Sandu Pharmaceuticals appoints Viswanathan as Chairman and MD

1 min read Updated on 11 Jul 2026, 08:05 PM

Reviewed by

Shriram SScanX News Team

AI Summary

Sandu Pharmaceuticals Limited has redesignated Shri Balram Viswanathan as Chairman and Managing Director for a term of three years effective July 11, 2026. The board also appointed Dr. Neeti Madan Kapre as an Additional Non-Executive Independent Director for a five-year term. These decisions follow the demise of former Managing Director Shri Umesh B. Sandu on June 19, 2026.

*this image is generated using AI for illustrative purposes only.

Board Appointments and Redesignations

The board approved the redesignation of Shri Balram Viswanathan from Chairman and Non-Executive Independent Director to Chairman and Managing Director. His appointment is subject to shareholder approval at the ensuing general meeting. Additionally, Dr. Neeti Madan Kapre was appointed as an Additional Non-Executive Independent Director effective July 11, 2026, until July 10, 2031, subject to shareholder approval.

Committee Reconstitution and Policy Updates

Pursuant to the leadership changes, the board reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee. The board also revised the Vigil Mechanism Policy to replace the name of the late Shri Umesh B. Sandu with Shri Balram Viswanathan as the Chairman and Managing Director.

Key Appointments Summary

Name	Position	Term
Shri Balram Viswanathan	Chairman and Managing Director	3 years (July 11, 2026 to July 10, 2029)
Dr. Neeti Madan Kapre	Additional Non-Executive Independent Director	5 years (July 11, 2026 to July 10, 2031)

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Sandu Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.06%	-0.85%	-2.54%	+2.17%	-18.57%	-20.00%

What strategic shifts can investors expect under Balram Viswanathan's leadership as he transitions to an executive role?

How will the shareholder approval process for these appointments impact the company's short-term stock performance?

What criteria will the board use to evaluate Viswanathan's performance over the three-year term?

Read Next Article

Sandu Pharmaceuticals Managing Director Umesh Sandu passes away

0 min read Updated on 19 Jun 2026, 04:35 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Sandu Pharmaceuticals Limited announced the demise of its Managing Director and Promoter, Shri Umesh Sandu, on June 19, 2026. The company noted his passing as an irreparable loss and stated that he ceased to be a member of the Audit Committee and Stakeholders Relationship Committee. The disclosure was made to the stock exchange in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals Limited announced the demise of its Managing Director and Promoter, Shri Umesh Sandu, on June 19, 2026. The company described his passing as an irreparable loss, noting that it had immensely benefitted from his vision and active participation in various committee and board meetings during his tenure. Consequently, he ceases to be a member of the Audit Committee and Stakeholders Relationship Committee.

The Chairman, all Directors, and employees of the company conveyed deep sympathy and condolences to his family members. The intimation was submitted to the stock exchange in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.